Abstract

Osteoprotegerin (OPG) and B-type natriuretic peptide (BNP) are cardiovascular risk factors, interrelated with each other, with possible associations with insulin sensitivity and glucose homeostasis. The aim of this study was to assess association between OPG and BNP concentrations in a young healthy population, their relation to insulin sensitivity and obesity and their regulation by hyperinsulinemia and serum free fatty acids (FFA) elevation. The study group consisted of 59 male volunteers, 30 of whom were of a normal weight (BMI < 25 kg/m2), and 29 were overweight/obese (BMI > 25 kg/m2). Insulin sensitivity was assessed with the 2-h hyperinsulinemic-euglycemic clamp (HEC). In the subgroup of 20 subjects, the clamp was prolonged to 6 h. After one week, another 6-h clamp, with concurrent Intralipid/heparin infusion, was performed. Serum OPG was positively associated with insulin sensitivity (p = 0.002) and negatively with BMI (p = 0.019) and serum BNP (p = 0.025). In response to 6-h hyperinsulinemia, circulating BNP decreased (p < 0.001). In response to HEC with Intralipid/heparin infusion, OPG decreased (p < 0.001) and BNP increased (p < 0.001). Our data show that OPG and BNP are differentially regulated by FFA, which suggests their association with lipid-induced insulin resistance. The assessment of these cardiovascular risk factors should take into account both long-term and short-term effects associated with insulin resistance.

Highlights

  • Insulin resistance (IR) is associated with an increased risk of type 2 diabetes and cardiovascular diseases [1]

  • We demonstrated the influence of hyperinsulinemia with and wit Intralipid/heparin infusion on serum OPG and brain natriuretic peptide (BNP) concentrations in this population

  • Intralipid/heparin infusion on serum OPG and BNP concentrations in this popula is one of the first studies in which we investigated the effect of free fatty acids (FFA) on the concentrations

Read more

Summary

Introduction

Insulin resistance (IR) is associated with an increased risk of type 2 diabetes and cardiovascular diseases [1]. Osteoprotegerin (OPG) and B-type natriuretic peptide, initially called brain natriuretic peptide (BNP), are nonclassical cardiovascular risk factors, interrelated with each other [2], with possible associations with insulin sensitivity and glucose homeostasis. OPG inhibits osteoclastogenesis and bone resorption by acting as a decoy receptor for Receptor Activator for Nuclear Factor κ B Ligand (RANKL) in the RANK/RANKL/OPG axis [3]. It is secreted by diverse tissues, including the lung, kidney, immune tissues and the cardiovascular system [4]. We can find works describing the lack of a correlation between OPG and obesity [11,12], as well as describing a positive correlation between these factors [13]

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call